Graft versus host disease

This phase III trial tests whether adding low-dose methotrexate to standard corticosteroid treatment works better than steroids alone for adults who develop acute graft-versus-host disease after a stem cell transplant. Participants receive either methotrexate or a placebo alongsi…

This Phase II trial tests whether adding rituximab to standard first-line treatment with ciclosporine and corticosteroids improves remission rates in adults who develop chronic graft versus host disease after a stem cell transplant. Participants receive rituximab infusions once a…

This study follows about 140 people in Korea who have steroid-refractory graft-versus-host disease (GvHD) — a serious complication after a stem cell transplant where donor immune cells attack the recipient's body. Researchers are tracking how well the drug ruxolitinib (Jakavi) wo…

This phase 3 trial investigates whether adding alpha-1 antitrypsin (AAT) to standard corticosteroid therapy improves outcomes for people with high-risk acute graft-versus-host disease (GVHD) after a stem cell transplant. Participants receive either AAT plus steroids or a placebo …

This study tested a new drug called EQ001 in 30 people who developed acute graft-versus-host disease (aGVHD) after a stem cell transplant. aGVHD is a serious condition where donor immune cells attack the patient's body. The goal was to see if EQ001 is safe and can help control th…

This completed Phase 2 trial tested whether high-dose chemotherapy followed by a stem cell transplant could help people with breast cancer that responds to standard chemo. 203 patients with stage II, III, or IV breast cancer took part. The main goal was to see how long they survi…

This study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…

This study tests the drug abatacept in people with chronic graft-versus-host disease (cGVHD) that is not controlled by steroids. cGVHD is a condition where donor immune cells attack the recipient's body after a stem cell transplant. The trial has two phases: first, to find a safe…

This early study tested the drug belimumab (Benlysta) to see if it could prevent chronic graft-versus-host disease (GvHD) in 10 adults who had a stem cell transplant for blood cancer. GvHD is a serious condition where the donor's immune cells attack the patient's body. The main g…

This early-stage study tested whether adding a drug called BMS-986004 to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD occurs when donor immune cel…

This study tested whether adding pacritinib to standard immune-suppressing drugs (sirolimus and tacrolimus) could prevent graft-versus-host disease (GVHD) in 40 patients receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the recipient's …

This study looked at 100 liver transplant patients to see if using less immune-suppressing medication could lower the risk of graft-versus-host disease (GVHD), a serious condition where donor cells attack the recipient's body. Researchers tracked how many patients developed GVHD …

This study tested whether a low dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (GVHD) — a common and serious complication where donor cells attack the patient's body. The trial involved 35 adults with various blood dis…

This study tested the drug nilotinib in 65 adults with chronic graft-versus-host disease (GVHD) who did not respond to imatinib. GVHD is a complication after a stem cell transplant where donor cells attack the patient's body. The goal was to see if nilotinib could help control th…

This study tested whether giving the drug cyclophosphamide after a stem cell transplant could help prevent a serious complication called graft-versus-host disease (GVHD) in 78 blood cancer patients. The approach aimed to make transplants from less-than-perfect donors as safe and …

This study tested whether adding the drug ruxolitinib to standard steroids helps children with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. 46 children aged 28 days to 18 years took part. The main goal was to see how many had a complete o…

This study tested whether adding the drug abatacept to standard medications (calcineurin inhibitor and methotrexate) could better prevent severe acute graft-versus-host disease (aGVHD) after a stem cell transplant from an unrelated donor. A total of 186 participants aged 6 and ol…

This phase 2 study tested a stem cell product called Prochymal in 11 patients with severe graft-versus-host disease (GVHD) that did not improve with standard treatments. The goal was to see if the infusion could reduce or resolve GVHD symptoms by day 28. The study measured comple…

This study tested the drug ibrutinib in 59 children with chronic graft-versus-host disease (cGVHD), a serious condition that can occur after a stem cell transplant. The goal was to find the best dose and see if it is safe. Participants had moderate or severe cGVHD that did not im…

This study tested whether the drug tildrakizumab could help prevent graft-versus-host disease (GVHD) in 51 adults receiving a stem cell transplant for blood cancers. GVHD is a serious complication where donor cells attack the patient's body. The goal was to see if adding tildraki…

This study tested a drug called pomalidomide in 34 adults with chronic graft-versus-host disease (GvHD) that didn't improve with standard treatments. GvHD can happen after a stem cell transplant when the donor cells attack the recipient's body. Participants took pomalidomide caps…

This study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the risk of chronic graft-versus-host disease (GVHD) after a stem cell transplant in people with high-risk blood cancers. GVHD happens when donor cells attack the patient's body. The…

This study tested whether a procedure called extracorporeal photophoresis (ECP) could prevent graft-versus-host disease (GVHD) in 158 people receiving stem cell transplants for blood cancers. ECP involves removing white blood cells, treating them with a light-sensitive drug and U…

This large Phase 3 study tested whether adding the drug itacitinib to standard steroids helps control acute graft-versus-host disease (GVHD) in people who had a stem cell transplant for blood cancer. About 439 participants received either itacitinib or a placebo along with steroi…

This small Phase 1 study tested whether a radioactive tracer called [18F]F-AraG can help detect graft-versus-host disease (GVHD) using PET scans. GVHD is a serious condition where donor immune cells attack the recipient's body after a stem cell transplant. The study involved 9 pa…

This trial tests whether a single high dose of vitamin A, given before a donor stem cell transplant, can prevent gastrointestinal graft-versus-host disease (GVHD), a condition where donor cells attack the gut. Vitamin A deficiency is linked to a higher risk of this complication, …

This phase II trial tested whether giving high doses of cyclophosphamide and bortezomib after a stem cell transplant could prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Twenty-three adults with blood cancers received…

This study tested whether the drug obinutuzumab can prevent chronic graft-versus-host disease (cGVHD), a common and serious complication after a stem cell transplant. 181 people who had a stem cell transplant took part. The goal was to see if obinutuzumab could reduce the need fo…

This study tested whether CAM-101 eye drops are safe and can help relieve dry eye in people who developed the condition after a bone marrow transplant (graft-versus-host disease). 64 adults received either a low or high dose of CAM-101 or a placebo drop four times a day for six w…

This study tested whether eye drops made from a patient's own blood (autologous serum) can relieve severe dry eye better than standard artificial tears. 46 adults with severe dry eye tried both diluted (20%) and full-strength (100%) serum drops, as well as artificial tears. The m…

This study followed 190 adults who had or were about to have a stem cell transplant from a donor. Researchers tracked changes in the mouth, like dryness or sores, to learn more about chronic graft-versus-host disease (cGVHD). Participants provided saliva, mouth swabs, and had den…

This study looked at whether counting a specific type of cell in the blood (circulating endothelial cells) can predict the risk of acute graft-versus-host disease (GVHD) in adults receiving a stem cell transplant for blood cancer. Researchers measured these cells before transplan…

This study looked at 70 patients who had a stem cell transplant for blood cancer. Researchers measured levels of complement proteins in the blood to see if they are linked to graft-versus-host disease, a common and serious side effect. The goal is to better understand how inflamm…

This study looked at whether specially engineered versions of a natural immune protein (IL-2) can selectively boost regulatory T cells, which help calm the immune system. Researchers took blood samples from 67 people with various autoimmune or inflammatory conditions and tested t…